Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | PGK2 | P07205 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 3/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | ACP3 | P15309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8703505 | 0.82 | FDPS (0.47) | FDPSPTPN1SMN1; SMN2HIF1APTPRC | |
| SCHEMBL29510761 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2HIF1ACES1 | |
| SCHEMBL28369074 | 0.79 | SMN1; SMN2 (0.50) | FDPSPTPN1SMN1; SMN2HIF1APTPRC | |
| SCHEMBL7316714 | 0.79 | SMN1; SMN2 (0.50) | FDPSPTPN1SMN1; SMN2HIF1APTPRC | |
| SCHEMBL6248908 | 0.75 | PTPN1 (0.43) | FDPSPTPN1SMN1; SMN2HIF1APTPRC | |
| SCHEMBL30887346 | 0.75 | SMN1; SMN2 (0.50) | FDPSPTPN1SMN1; SMN2HIF1ACES1 | |
| SCHEMBL3736878 | 0.75 | SMN1; SMN2 (0.50) | FDPSPTPN1SMN1; SMN2HIF1ACES1 | |
| SCHEMBL29112713 | 0.75 | SMN1; SMN2 (0.50) | FDPSPTPN1SMN1; SMN2HIF1ACES1 | |
| SCHEMBL26127150 | 0.73 | SMN1; SMN2 (0.44) | FDPSPTPN1SMN1; SMN2HIF1ACES1 | |
| SCHEMBL8414267 | 0.69 | PTPN1 (0.39) | FDPSPTPN1PTPRCPGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148715-A1 | Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands | BAYLOR COLLEGE OF MEDICINE (US) | 2006-07-06 | — | — | US | claimed |
| WO-2006069001-A2 | STRUCTURAL REQUIREMENTS FOR STAT3 BINDING AND RECRUITMENT TO PHOSPHOTOTYROSINE LIGANDS | BAYLOR COLLEGE OF MEDICINE (US) | 2006-06-29 | — | — | WO | claimed |
| US-5801149-A | PEPTIDS FOR INHIBITION OF PROTEINS | JOSLIN D-ABETES CENTER, INC. (US) | 1998-09-01 | — | — | US | claimed |
| WO-1994008600-A1 | INHIBITION OF SIGNAL TRANSDUCTION MOLECULES | JOSLIN DIABETES CENTER (US) | 1994-04-28 | — | — | WO | claimed |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260115301-A1 | INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4717776-A2 | POLYPEPTIDE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | Ohio State Innovation Foundation (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4706689-A2 | COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS | Entrada Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12496350-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | OHIO STATE INNOVATION FOUNDATION (US) | 2025-12-16 | — | — | US | disclosed |
| US-12454552-B2 | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250324980-A1 | COMPOSITIONS FOR DELIVERY OF AGENTS INTO PLANT CELLS | OHIO STATE INNOVATION FOUNDATION (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250270258-A1 | BICYCLIC PEPTIDYL INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2025-08-28 | — | — | US | disclosed |
| US-5650293-A | PROTEIN THAT MEDIATES INSULIN REGULATION OF 3'-PHOSPHATIDYL INOSITOL KINASE WITH NUCLEIC ACID SEQUENCES | JOSLIN DIABETES CENTER, INC. (US) | 1997-07-22 | — | — | US | disclosed |
| WO-1997008300-A9 | CRYSTALLINE ZAP FAMILY PROTEINS | — | 1997-05-22 | — | — | WO | disclosed |
| EP-0768821-A1 | pp60PIK : A DOWNSTREAM ELEMENT IN INSULIN SIGNALING | THE JOSLIN DIABETES CENTER, INC. (US) | 1997-04-23 | — | — | EP | disclosed |
| WO-1995034201-A1 | pp60PIK: A DOWNSTREAM ELEMENT IN INSULIN SIGNALING | JOSLIN DIABETES CENTER, INC. (US) | 1995-12-21 | — | — | WO | disclosed |
| US-5475129-A | Phosphonoalkyl phenylalanine compounds suitably protected for use in peptide synthesis | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1994008600-A1 | INHIBITION OF SIGNAL TRANSDUCTION MOLECULES | JOSLIN DIABETES CENTER (US) | 1994-04-28 | — | — | WO | disclosed |
| WO-1993025561-A1 | PHOSPHONOALKYL PHENYLALANINE COMPOUNDS SUITABLY PROTECTED FOR USE IN PEPTIDE SYNTHESIS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-12-23 | — | — | WO | disclosed |
| US-5264607-A | Process of making benzylic α,α-diflurophosphonates from benzylic α-ketophosphorates | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115301-A1 | INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | SLC7A1, SRM, SLC6A19 | FDPS 4277/4885PTPN1 4249/4885SMN1; SMN2 231/4885 |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, SLC7A1, SLC6A15 | FDPS 4608/4885PTPN1 4155/4885SMN1; SMN2 1836/4885 |
| US-20250324980-A1 | COMPOSITIONS FOR DELIVERY OF AGENTS INTO PLANT CELLS | ARGLU1, PHAX, VMA21 | FDPS 2954/4885PTPN1 4632/4885SMN1; SMN2 4524/4885 |
| US-12454552-B2 | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof | CHN2, TAP2, VIP | FDPS 3735/4885PTPN1 4477/4885SMN1; SMN2 2867/4885 |
| US-20060148715-A1 | Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands | STAT3, JAK2, STAT5B | FDPS 3470/4885PTPN1 60/4885SMN1; SMN2 4364/4885 |
| US-20250270258-A1 | BICYCLIC PEPTIDYL INHIBITORS | NFKBIA, IKBKG, NFRKB | FDPS 2620/4885PTPN1 4339/4885SMN1; SMN2 4522/4885 |
| US-12496350-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | CNBP, CALU, CLSPN | FDPS 2927/4885PTPN1 666/4885SMN1; SMN2 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.